SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001213900-21-007001
Filing Date
2021-02-05
Accepted
2021-02-05 10:12:31
Documents
1
Group Members
PONTIFAX (CAYMAN) II L.P.PONTIFAX (ISRAEL) II L.P.PONTIFAX MANAGEMENT 2 G.P. (2007) LTD.PONTIFAX MANAGEMENT II L.P.TOMER KARIV

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO.1 TO SCHEDULE 13G ea134669-sc13ga1nuss_purple.htm SC 13G/A 144020
  Complete submission text file 0001213900-21-007001.txt   145725
Mailing Address C/O KITE PHARMA, INC. 2225 COLORADO AVENUE SANTA MONICA CA 90404
Business Address
Nussbaum Ran (Filed by) CIK: 0001609805 (see all company filings)

Type: SC 13G/A

Mailing Address 4 OPPENHEIMER STREET SCIENCE PARK REHOVOT L3 7670104
Business Address 4 OPPENHEIMER STREET SCIENCE PARK REHOVOT L3 7670104 97239333121
PURPLE BIOTECH LTD. (Subject) CIK: 0001614744 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-89209 | Film No.: 21594419
SIC: 2834 Pharmaceutical Preparations